Millennium Management’s Prevail Therapeutics PRVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
– Sell
-27,400
Closed -$632K – 6866
2020
Q4
$632K Buy
+27,400
New +$347K ﹤0.01% 4030

Millennium Management's PRVL Position: Q1 2021 in Review

Millennium Management sold out of Prevail Therapeutics (PRVL) in Q1 2021, closing a stake of 589,987 shares — an estimated $13.6M sold.

Millennium Management first reported a position in PRVL in Q2 2019 and held it in 6 quarters. The position peaked at $13.6M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Millennium Management reported no remaining Prevail Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Millennium Management sold 589,987 Prevail Therapeutics shares in Q1 2021, an estimated $13.6M.
  • Millennium Management first reported a position in Prevail Therapeutics in Q2 2019 and held it in 6 quarters.
  • Millennium Management's Prevail Therapeutics position peaked at $13.6M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q1 2021.

Based on Millennium Management's 13F filing for Q1 2021, filed 17 May 2021.